预防高危因素患者肝癌切除术后复发的治疗进展

doi:10.3969/j.issn.1009-976X.2023.02.014

摘要/Abstract

摘要： 肝癌术后的高复发及转移率仍然是阻碍着患者生存的障碍,降低复发是改善肝切除术后预后的关键。针对肝癌术后存在高复发和转移风险,目前尚无预防和治疗的标准方案。本文讨论了可能降低肝癌术后复发风险并提高生存率的辅助治疗方案的进展,包括肝动脉化疗栓塞、分子靶向药物和免疫疗法的辅助全身治疗、抗病毒和其它局部治疗以及潜在的联合治疗。选择具有个性化的联合治疗模式可能是防治HCC术后复发的发展趋势,但这仍需要进一步验证。

关键词: 肝细胞癌, 复发, 辅助治疗, TACE, 免疫治疗, 化疗, 靶向治疗

Abstract: The high recurrence rate and metastasis of hepatocellular carcinoma（HCC） after surgery still hinders the improvement of patients' survival. Reducing the recurrence rate after hepatectomy is the key prolonging the recurrence-free survival and reducing extrahepatic recurrence. For patients with high risk of recurrence after surgery, there is no standard therapy procedure to prevent recurrence after radical resection of HCC. This article discusses the progress of adjuvant therapy that may reduce the risks of recurrence and improve the survival rate after hepatectomy, including transcatheter arterial chemoembolization （TACE）, molecular targeted therapy and adjuvant immunotherapy, antiviral and other local therapies, and combination therapy. The paradigm with selective personalized combination therapy may be the development trend of prevention and treatment of postoperative recurrence of HCC, but this still needs further research for verification.

Key words: hepatocellular carcinoma, currrence, adjuvant therapy, TACE, immunotherapy, chemotherapy, targeted therapy

中图分类号:

R735.7

管玉婷, 曾国斌, 陈建平, 吴雄健. 预防高危因素患者肝癌切除术后复发的治疗进展[J]. 岭南现代临床外科, 2023, 23(02): 193-199.

GUAN Yu-ting, ZENG Guo-bin, CHEN Jian-ping, WU Xiong-jian. Advance of adjuvant therapy after curative resection for hepatocellular carcinoma[J]. Lingnan Modern Clinics In Surgery, 2023, 23(02): 193-199.

参考文献

[1] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] 曹毛毛, 李贺, 孙殿钦,等.全球肝癌2020年流行病学现状[J]. 中华肿瘤防治杂志2022, 29(5): 322-328.
[3] Llovet JM, Kelley RK, Villanueva A, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6.
[4] 宋天强. 肝癌外科治疗策略的转变与挑战[J]. 中华外科杂志, 2021, 59(6): 447-451.
[5] 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 中华外科杂志, 2022, 60(4): 273-309.
[6] 中华医学会肝病学分会. 原发性肝癌三级预防共识(2022年版)[J]. 中华肝脏病杂志2022, 30(8): 832-845.
[7] Shinkawa H, Tanaka S, Takemura S, et al.Nomograms redicting extra- and early intrahepatic recurrence after hepatic resection of hepatocellular carcinoma[J]. Surgery, 2021, 169(4): 922-928.
[8] Liang BY, Gu J, Xiong M, et al.Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy[J]. Sci Rep, 2021, 11(1): 16343.
[9] Zhang K, Tao C, Siqin T, et al.Establishment, validation and evaluation of predictive model for early relapse after R0 resection in hepatocellular carcinoma patients with microvascular invasion[J]. J Transl Med, 2021, 19(1): 293.
[10] Erstad DJ, Tanabe KK.Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma[J]. Ann Surg Oncol, 2019, 26(5): 1474-1493.
[11] Zhang X, Li J, Shen F, et al.Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2018, 33(2): 347-354.
[12] Zhang W, Zhang B, Chen XP.Adjuvant treatment strategy after curative resection for hepatocellular carcinoma[J]. Front Med, 2021, 15(2): 155-169.
[13] 中华医学会肝病学分会.原发性肝癌三级预防共识(2022年版)[J]. 中华肝脏病杂志,2022, 30(8): 832-845.
[14] Xu XF, Xing H, Han J, et al.Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China[J]. JAMA Surg, 2019, 154(3): 209-217.
[15] Wang Z, Ren Z, Chen Y, et al.Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study[J]. Clin Cancer Res, 2018, 24(9): 2074-2081.
[16] Chen ZH, Zhang XP, Zhou TF, et al.Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: a systematic review and meta-analysis[J]. Eur J Surg Oncol, 2019, 45(11): 2188-2196.
[17] Wei W, Jian PE, Li SH, et al.Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety[J]. Cancer Commun (Lond), 2018, 38(1): 61.
[18] Chen W, Ma T, Zhang J, et al.A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma[J]. HPB (Oxford), 2020, 22(6): 795-808.
[19] Shen A, Liu M, Zheng D, et al.Adjuvant transarterialchemoembolization after curative hepatectomy for hepatocellularcarcinoma with microvascular invasion: a systematic review andmeta-analysis[J]. Clin Res Hepatol Gastroenterol, 2020, 44(2): 142-154.
[20] Qiu JF, Ye JZ, Feng XZ, et al.Pre- and post-operative HBsAg levels may predict recurrence and survival after curative resection in patients with HBV-associated hepatocellular carcinoma[J]. J Surg Oncol, 2017, 116(2): 140-148.
[21] Yin J, Li N, Han Y, et al.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study[J]. J Clin Oncol, 2013, 31(29): 3647-3655.
[22] Yuan P, Chen P, Qian Y.Evaluation of antiviral therapy performed after curative therapy in patients with HBV-related hepatocellular carcinoma: An updated meta-analysis[J]. Can J Gastroenterol Hepatol, 2016, 2016: 5234969.
[23] 中华医学会肝病学分会肝炎学组.非一线核苷(酸)类似物经治慢性乙型肝炎患者治疗策略调整专家共识[J]. 中华肝脏病杂志,2019,27(5): 343-346.
[24] Singal AK, Salameh H, Kuo YF, Fontana RJ.Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2013, 38(2): 98-106.
[25] Huang G, Lau WY, Wang ZG, et al.Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial[J]. Ann Surg, 2015, 261(1): 56-66.
[26] Huang G, Li PP, Lau WY, et al.Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial[J]. Ann Surg, 2018, 268(6): 943-954.
[27] Huang L, Li J, Yan J, et al.Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial[J]. J Viral Hepat, 2013, 20(5): 336-342.
[28] Chen LT, Jeng LB, Hsiao CF, et al.Randomized, phase III trial of adjuvant adeforvir vs. therapeutic lamivudine in post-operative BCLC stage 0 or A HBV-related HCC: the Taiwan Cooperative Oncology Group T1206 study[J]. J Clin Oncol, 2015, 33(15_suppl): 4101.
[29] Fox DS, McGinnis JJ, Tonnu-Mihara IQ, McCombs JS. Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: data from the Veterans Administration[J]. J Gastroenterol Hepatol, 2017, 32(6): 1136-1142
[30] Singal AG, Rich NE, Mehta N, et al. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma [J]. Gastroenterology, 2019, 157(5): 1253-1263.e2.
[31] Cabibbo G, Celsa C, Calvaruso V, et al.Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients[J]. J Hepatol, 2019, 71(2): 265-273.
[32] Conti F, Buonfiglioli F, Scuteri A, et al.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals[J]. J Hepatol, 2016, 65(4): 727-733.
[33] Rajendran L, Choi WJ, Muaddi H, et al.Association of Viral Hepatitis Status and Post-hepatectomy Outcomes in the Era of Direct-Acting Antivirals[J]. Ann Surg Oncol, 2023, 30(5): 2793-2802.
[34] Sangro B, Sarobe P, Hervás-Stubbs S, Melero I.Advances in immunotherapy for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(8): 525-543.
[35] Kudo M, Finn RS, Qin S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018,391(10126): 1163-1173.
[36] Sperandio RC, Pestana RC, Miyamura BV, Kaseb AO.Hepatocellular Carcinoma Immunotherapy[J]. Annu Rev Med, 2022, 73: 267-278.
[37] Borcoman E, Kanjanapan Y, Champiat S, et al.Novel patterns of response under immunotherapy[J]. Ann Oncol, 2019, 30(3): 385-396.
[38] El-Khoueiry AB, Sangro B, Yau T, et al.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-502
[39] Zhu AX, Finn RS, Edeline J, et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952.
[40] Finn RS, Ikeda M, Zhu AX, et al.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J. Clin Oncol, 2020, 38(26): 2960-2970.
[41] Zhu Y, Chen M, Xu D, et al.The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma[J]. Cell Mol Immunol, 2022, 19(6): 726-737.
[42] Hu B, Yu M, Ma X, et al.IFNα Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment[J]. Cancer Discov, 2022, 12(7): 1718-1741.
[43] Hasegawa K, Takayama T, Ijichi M, et al.Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial[J]. Hepatology, 2006, 44(4): 891-895.
[44] Xia Y, Qiu Y, Li J, et al.Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial[J]. Ann Surg Oncol, 2010, 17(12): 3137-44.
[45] Ishizuka M, Kubota K, Nemoto T, et al.Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial[J]. Asian J Surg,2016, 39(3): 149-154.
[46] Zeng ZM, Mo N, Zeng J, et al.Advances in postoperative adjuvant therapy for primary liver cancer[J]. World J Gastrointest Oncol, 2022, 14(9): 1604-1621.
[47] Feng M, Tang C, Feng W, et al.Hepatic artery-infusion chemotherapy improved survival of hepatocellular carcinoma after radical hepatectomy[J]. Onco Targets Ther, 2017, 10: 3001-3005.
[48] Gao Y, Wang PX, Cheng JW, et al.Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis[J]. Cancer Med, 2019, 8(16): 6933-6944.
[49] Hamada T, Yano K, Wada T, et al.Increased Survival Benefit of Adjuvant Intra-arterial Infusion Chemotherapy in HCC Patients with Portal Vein Infiltration after Hepatectomy[J]. World J Surg, 2020, 44(8): 2770-2776.
[50] Hsiao JH, Tsai CC, Liang TJ, et al.Adjuvant hepatic arterial infusion chemotherapy is beneficial for selective patients with Hepatocellular carcinoma undergoing surgical treatment[J]. Int J Surg, 2017, 45: 35-41.
[51] Li S, Mei J, Wang Q, et al.Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX Could Improve Outcomes of Hepatocellular Carcinoma Patients with Microvascular Invasion: A Preliminary Report of a Phase III, Randomized Controlled Clinical Trial[J]. Ann Surg Oncol, 2020, 27(13): 5183-5190.
[52] Gou XX, Shi HY, Li C, et al.Association of adjuvant radiation therapy with long-term overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a multicenter propensity-matched study[J]. Int J Radiat Oncol Biol Phys, 2022, 114(2): 238-249.
[53] Wang L, Qiu L, Ke Q, et al.Systematic review of adjuvant external beam radiotherapy for hepatocellular carcinoma following radical hepatectomy[J]. Radiother Oncol, 2022, 175: 101-111.
[54] Yu W, Wang W, Rong W, et al.Adjuvant radiotherapy in centrally located hepatocellular carcinomas after hepatectomy with narrow margin (<1 cm): a prospective randomized study[J]. J Am Coll Surg, 2014, 218(3):381-392.
[55] Sun J, Yang L, Shi J, et al.Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: An open-label randomized controlled trial[J]. Radiother Oncol, 2019, 140: 20-25.
[56] Lau WY, Leung TW, Ho SK, et al.Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial[J]. Lancet, 1999, 353(9155): 797-801.
[57] Chung AY, Ooi LL, Machin D, et al.Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial[J]. World J Surg, 2013, 37(6):1356-1361.
[58] Furtado R, Crawford M, Sandroussi C.Systematic review and meta-analysis of adjuvant 131I lipiodol after excision of hepatocellular carcinoma[J]. Ann Surg Oncol, 2014, 21(8):2700-2707.
[59] Gong L, Shi L, Sun J, et al.Comparative survival analysis of adjuvant therapy with iodine-131-labeled lipiodol to hepatic resection of primary hepatocellular carcinoma: a meta-analysis[J]. Nucl Med Commun, 2014, 35(5): 484-492.
[60] Li J, Xing J, Yang Y, et al.Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2020, 5(6): 548-560.
[61] de la Torre-Aláez M, Matilla A, Varela M, et al. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study[J]. J Immunother Cancer, 2022, 10(11):e005457.
[62] Feng X, Zhang L, Niu H, et al. Selective internal radiation therapy with yttrium-90 resin microspheres followed by anatomical hepatectomy: A potential curative strategy in advanced hepatocellular carcinoma [J]. Asia Pac J Clin Oncol, 2023 Jan 19. doi: 10.1111/ajco.13900.